ProMetic Life Sciences Inc. (TSE:PLI)‘s stock had its “outperform” rating reaffirmed by equities research analysts at Royal Bank Of Canada in a note issued to investors on Thursday, reports.

PLI has been the topic of several other reports. TD Securities reissued a “speculative buy” rating and issued a C$4.50 target price on shares of ProMetic Life Sciences in a research report on Wednesday, September 28th. Scotiabank reissued an “outperform” rating and issued a C$5.00 target price on shares of ProMetic Life Sciences in a research report on Thursday, August 25th. Finally, CIBC dropped their target price on shares of ProMetic Life Sciences from C$5.00 to C$4.85 in a research report on Thursday, August 25th. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of C$4.84.

Analyst Recommendations for ProMetic Life Sciences (TSE:PLI)

Shares of ProMetic Life Sciences (TSE:PLI) traded down 1.89% during trading on Thursday, hitting $3.11. 520,719 shares of the stock were exchanged. The stock’s 50 day moving average is $2.92 and its 200-day moving average is $3.01. The stock’s market cap is $1.88 billion. ProMetic Life Sciences has a 12-month low of $1.67 and a 12-month high of $3.62.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at

ProMetic Life Sciences Company Profile

ProMetic Life Sciences Inc (ProMetic) is a Canada-based biopharmaceutical company. The Company has two segments: Small Molecule Therapeutics and Protein Technology. The Company offers its technology platform for large-scale drug purification of biologics, drug development, proteomics and the elimination of pathogens to various industries, and uses its own affinity technology that provides for extraction and purification of therapeutic proteins from human plasma in order to develop therapeutics and orphan drugs.

Stock Target Prices

Receive News & Ratings for ProMetic Life Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMetic Life Sciences Inc. and related companies with's FREE daily email newsletter.